Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas

被引:16
|
作者
Wong E.T. [1 ,2 ]
Alsop D. [3 ]
Lee D. [1 ,2 ]
Tam A. [1 ,2 ]
Barron L. [1 ,2 ]
Bloom J. [1 ,2 ]
Gautam S. [3 ]
Wu J.K. [1 ,3 ,4 ]
机构
[1] Beth Israel Deaconess Medical Center, Brain Tumor Center and Neuro-Oncology Unit, Boston
[2] Beth Israel Deaconess Medical Center, Department of Neurology, Boston
[3] Beth Israel Deaconess Medical Center, Division of Neuroradiology, Boston
[4] Tufts-New England Medical Center, Department of Neurosurgery, Boston
来源
Cerebrospinal Fluid Research | / 5卷 / 1期
关键词
Epidermal Growth Factor Receptor; Irinotecan; Thalidomide; Doxycycline; Malignant Glioma;
D O I
10.1186/1743-8454-5-1
中图分类号
学科分类号
摘要
Background: Matrix metalloproteinases (MMPs) are enzymes that promote tumor invasion and angiogenesis by enzymatically remodeling the extracellular matrix. MMP-2 and MMP-9 are the most abundant forms of MMPs in malignant gliomas, while a 130 kDa MMP is thought to be MMP-9 complexed to other proteinases. This study determined whether doxycycline can block MMP activity in vitro. We also measured MMP-2 and MMP-9 levels in cerebrospinal fluid (CSF) from patients with recurrent malignant gliomas. Methods: To determine whether doxycycline can block MMP activity, we measured the extent of doxycyline-mediated MMP-2 and MMP-9 inhibition in vitro using epidermal growth factor receptor (EGFR) transfected U251 glioma cell lines. MMP activity was measured using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) zymography. In addition, patients underwent lumbar puncture for CSF sampling at baseline, after 6 weeks (1 cycle), and after 12 weeks (2 cycles), while being treated with a novel chemotherapy regimen of irinotecan, thalidomide, and doxycycline designed to block growth/proliferation, angiogenesis, and invasion. Irinotecan was given at 125 mg/m2/week for 4 weeks in 6-week cycles, together with continuous doxycycline at 100 mg twice daily on Day 1 and 50 mg twice daily thereafter. Daily thalidomide dose in our cohort was 400 mg. Tumor progression was monitored by magnetic resonance imaging (MRI). Results: Doxycyline in vitro completely abolished MMP-9 activity at 500 μg/ml while there was only 30 to 50% inhibition of MMP-2 activity. Four patients respectively completed 4, 3, 1, and 2 cycles of irinotecan, thalidomide, and doxycycline. Patient enrollment was terminated after one patient developed radiologically defined pulmonary embolism, and another had probable pulmonary embolism. Although CSF MMP-2 and 130 kDa MMP levels were stable, MMP-9 level progressively increased during treatment despite stable MRI. Conclusion: Doxycycline can block MMP-2 and MMP-9 activities from glioma cells in vitro. Increased CSF MMP-9 activity could be a biomarker of disease activity in patients with malignant gliomas, before any changes are detectable on MRI. © 2008 Wong et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
  • [1] Levels of matrix metalloproteinase-2 and metalloproteinase-9 in the cerebrospinal fluid of dogs with visceral leishmaniasis
    Marangoni, N. R.
    Melo, G. D.
    Moraes, O. C.
    Souza, M. S.
    Perri, S. H. V.
    Machado, G. F.
    PARASITE IMMUNOLOGY, 2011, 33 (06) : 330 - 334
  • [2] Upregulation of matrix metalloproteinase-9 in the cerebrospinal fluid of patients with acute Lyme neuroborreliosis
    Kirchner, A
    Koedel, U
    Fingerle, V
    Paul, R
    Wilske, B
    Pfister, HW
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (03): : 368 - 371
  • [3] Matrix Metalloproteinase-9 in the Ventricular Cerebrospinal Fluid Correlated with the Prognosis of Traumatic Brain Injury
    Liu, Chun-Lin
    Chen, Chun-Chang
    Lee, Han-Chung
    Cho, Der-Yang
    TURKISH NEUROSURGERY, 2014, 24 (03) : 363 - 368
  • [4] Cerebrospinal fluid levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in subacute sclerosing panencephalitis
    Ichiyama, Takashi
    Matsushige, Takeshi
    Siba, Peter
    Suarkia, Dagwin
    Takasu, Toshiaki
    Miki, Kenji
    Furukawa, Susumu
    JOURNAL OF INFECTION, 2008, 56 (05) : 376 - 380
  • [5] Role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in patients with recurrent miscarriage
    Obayashi, Y.
    Ozaki, Y.
    Kurakane, S.
    Goto, S.
    Kumagai, K.
    Kitaori, T.
    Suzumori, N.
    Sugiura, M.
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2014, 106 : 20 - 20
  • [6] Levels of matrix metalloproteinase-9 within cerebrospinal fluid in a rabbit model of coccidioidal meningitis and vasculitis
    Williams, PL
    Leib, SL
    Kamberi, P
    Leppert, D
    Sobel, RA
    Bifrare, YD
    Clemons, KV
    Stevens, DA
    JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (11): : 1692 - 1695
  • [7] Matrix metalloproteinase-9 during cardiopulmonary bypass
    Galley, HF
    Macaulay, GD
    Webster, NR
    ANESTHESIOLOGY, 2000, 93 (3A) : U138 - U138
  • [8] Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas
    Iwamoto, Fabio M.
    Hottinger, Andreas F.
    Karimi, Sasan
    Riedel, Elyn
    Dantis, Jocelynn
    Jahdi, Maryam
    Panageas, Katherine S.
    Lassman, Andrew B.
    Abrey, Lauren E.
    Fleisher, Martin
    DeAngelis, Lisa M.
    Holland, Eric C.
    Hormigo, Adilia
    JOURNAL OF NEURO-ONCOLOGY, 2011, 105 (03) : 607 - 612
  • [9] Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas
    Fabio M. Iwamoto
    Andreas F. Hottinger
    Sasan Karimi
    Elyn Riedel
    Jocelynn Dantis
    Maryam Jahdi
    Katherine S. Panageas
    Andrew B. Lassman
    Lauren E. Abrey
    Martin Fleisher
    Lisa M. DeAngelis
    Eric C. Holland
    Adília Hormigo
    Journal of Neuro-Oncology, 2011, 105 : 607 - 612
  • [10] Matrix metalloproteinase-9 increases the risk of cognitive impairment in schizophrenia
    Keshri, Neha
    Nandeesha, Hanumanthappa
    Rajappa, Medha
    Menon, Vikas
    NORDIC JOURNAL OF PSYCHIATRY, 2021, 75 (02) : 130 - 134